In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units.
Ozbek
Berna
B
Otük
Gülten
G
D000151:Acinetobacter Infections / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology*; D003091:Colistin / Q000494:pharmacology*; D003428:Cross Infection / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D004357:Drug Synergism; D006801:Humans; D007362:Intensive Care Units; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013407:Sulbactam / Q000494:pharmacology*; D013845:Thienamycins / Q000494:pharmacology*; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D000078304:Tigecycline; D000077731:Meropenem; D008911:Minocycline; D013407:Sulbactam; D003091:Colistin